Cite
HARVARD Citation
Mountzios, G. et al. (2019). Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. Annals of oncology. pp. 1686-1688. [Online].